Karyopharm disclosed it plans to sell itself in a bankruptcy process, with the parent of cell therapy developer Gamida Cell expected to act as lead bidder in a court-supervised auction. The company recently cut a forbearance deal to push debt payments, but it now faces limited options to continue operating as a standalone commercial-stage biotech. The restructuring highlights how financing constraints in blood cancer portfolios can quickly translate into asset sales. The transaction signals continued consolidation pressure across hematology drug development as capital markets assess pipeline durability and funding pathways.